Artificial intelligence is rapidly transforming the landscape of drug discovery, enabling faster and more accurate identification of therapeutic targets, prediction of biomolecular interactions, and design of novel molecules with tailored functions. In parallel, advances in structural biology, particularly cryo-electron microscopy and AI-based structure prediction, are providing unprecedented insights into the molecular mechanisms underlying human disease and therapeutic intervention. In this talk, I will discuss how the integration of AI and structural biology is opening new opportunities for therapeutic discovery and engineering, and how we are implementing these approaches in my lab at the CNIO. I will present emerging AI-driven strategies for protein and binder design, including BinderFlow, an integrated computational pipeline that combines generative protein design, structural prediction, and experimental validation. Using selected examples, I will illustrate how these technologies can be applied to the development of next-generation therapeutics. Together, these advances are beginning to reshape how we discover, understand, and engineer medicines at the molecular level.